This is the first study in humans to investigate the effects of glycine on the MMN in the ketamine model of schizophrenia. The results confirm a key role of the glutamate system for pre-attentive auditory processing deficits underlying the symptoms of schizophrenia. From a translational perspective, the MMN and its theta-band signature may serve as biomarkers to identify patients who may benefit from glutamatergic treatment options.
Ćurić et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: